Paolo Cianciulli

TL;DR: It is suggested that deferiprone may be as effective as deferoxamine in the treatment of thalassemia major with few mild and reversible side effects.

TL;DR: Hepatocellular carcinoma (HCC) frequently complicates hepatic cirrhosis secondary to viral infection or iron overload, and patients affected by thalassaemia syndromes have a theoretically high risk of developing the tumour.

TL;DR: The cohort of patients treated with oral deferiprone showed less myocardial iron burden and better global systolic ventricular function compared to the patients treatedwith oral deferasirox or subcutaneous desferrioxamine.

TL;DR: In thalassemia major patients at the dosages used in the real world, the combined DFP+DFO regimen was more effective in removing cardiac iron than DFO, and was superior in clearing hepatic iron than either DFO or DFP monotherapy.

TL;DR: The developed global method increased the accuracy in T2* assessment and significantly reduced the operator dependence and sampling errors and could be useful in the clinical arena for patients with borderline liver iron overload and/or requiring follow-up studies.